In vitro inactivation of SARS-CoV-2 using a povidone-iodine oral rinse

BMC Oral Health

Table 1 In vitro virucidal activity of 0.5% (w/v) PVP-I oral rinse formulation against SARS-CoV-2

	Tested concentration (%)	Incubation time	Virus titer^a	LRV^b
0.5% (w/v) PVP-I oral rinse	50	15 s	2.5	2.8
Placebo oral rinse	50		4.67	0.63
Positive control	50		1.3	4.0
Negative control	NA		5.3	–
0.5% (w/v) PVP-I oral rinse	50	30 s	< 0.67	> 4.0
Placebo oral rinse	50		4.5	0.17
Positive control	50		< 0.67	> 4.0
Negative control	NA		4.67	–
0.5% (w/v) PVP-I oral rinse	50	60 s	1.0	3.67
Placebo oral rinse	50		5.0	0
Positive control	50		< 0.67	> 4.0
Negative control	NA		4.67	–
0.5% (w/v) PVP-I oral rinse	50	5 min	< 0.67	> 4.0
Placebo oral rinse	50		4.67	0
Positive control	50		< 0.67	> 4.0
Negative control	NA		4.67	–

Samples were incubated at 22 ± 2 °C for designated exposure times of 15 s, 30 s, 60 s, and 5 min
Abbreviations: CCID₅₀, 50% cell culture infectious dose; LRV, log₁₀ reduction value; NA, not applicable; PVP-I, povidone-iodine; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; w/v, weight per volume
^aLog₁₀ CCID₅₀ of virus per 0.1 mL. The assay lower limit of detection is 0.67 log₁₀ CCID₅₀/0.1 mL
^bLRV is the reduction of the virus compared with that of the negative control

ISSN: 1472-6831